nelfinavir has been researched along with Kahler Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Besse, A; Besse, L; Driessen, C; Kraus, M; Tarantino, I | 1 |
| Besse, L; Driessen, C; Hess, D; Hitz, F; Kraus, M; Mey, U; Novak, U; Pabst, T; Rondeau, S; Samaras, P; Seipel, K; Silzle, T; Stüdeli, S; Vilei, SB | 1 |
| Allegra, A; Allegra, AG; Innao, V; Musolino, C; Pugliese, M; Pulvirenti, N | 1 |
| Gu, Y; Li, J; Wang, X; Wang, Y; Yu, FX | 1 |
| Berkers, CR; Besse, A; Besse, L; Bolomsky, A; Borén, J; Büchler, L; Driessen, C; Everts, B; Farhan, H; Florea, BI; Hannich, JT; Huber, J; Loguinov, A; Ludwig, H; Overkleeft, HS; Phuyal, S; Pilon, M; Ruiz, M; Sathianathan, M; Sobh, A; Ståhlman, M; Stolze, SC; van der Ham, AJ; Vulpe, CD; Zaal, EA | 1 |
| Bader, J; Besse, A; Besse, L; Driessen, C; Kraus, M; Morgan, GJ; Overkleeft, HS; Rasche, L; Stolze, SC; Weinhold, N | 1 |
| Berset, C; Besse, A; Besse, L; Betticher, D; Cantoni, N; Driessen, C; Hawle, H; Hitz, F; Mach, N; Mey, U; Müller, R; Novak, U; Pabst, T; Ribi, K; Rondeau, S; Rüfer, A; Samaras, P; Zander, T | 1 |
| Dorr, RT; Escalante, AM; Karolak, MR; Landowski, TH; Lynch, RM; McGrath, RT | 1 |
| Bader, J; Berset, C; Berthod, G; Driessen, C; Hawle, H; Hess, D; Hitz, F; Huitema, A; Joerger, M; Kraus, M; Mey, UJ; Overkleeft, HS; Pabst, T; Rosing, H; Sessa, C; von Moos, R; Xyrafas, A | 1 |
| Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H | 1 |
| Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W | 1 |
1 review(s) available for nelfinavir and Kahler Disease
| Article | Year |
|---|---|
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Drug Repositioning; Hematologic Neoplasms; Humans; Multiple Myeloma; Nelfinavir | 2020 |
3 trial(s) available for nelfinavir and Kahler Disease
| Article | Year |
|---|---|
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Dexamethasone; Female; HIV Protease Inhibitors; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nelfinavir | 2019 |
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Inhibitors; Treatment Outcome | 2018 |
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Leukemia; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Treatment Outcome; Unfolded Protein Response | 2016 |
7 other study(ies) available for nelfinavir and Kahler Disease
| Article | Year |
|---|---|
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2023 |
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Topics: Aspartic Acid Proteases; HCT116 Cells; HEK293 Cells; HIV Protease Inhibitors; Humans; Multiple Myeloma; Nelfinavir; Proteasome Inhibitors; Proteolysis | 2020 |
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; CRISPR-Cas Systems; Endoplasmic Reticulum; Genome; Glucose; Golgi Apparatus; HEK293 Cells; HIV Protease Inhibitors; Humans; Lipidomics; Lipids; Membrane Lipids; Multiple Myeloma; Nelfinavir; Phospholipids; Phosphorylation; Receptors, Adiponectin; Signal Transduction | 2021 |
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HIV Protease Inhibitors; Humans; Lopinavir; Multiple Myeloma; Nelfinavir; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2018 |
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calpain; Cell Line, Tumor; Cell Survival; Drug Synergism; HIV Protease Inhibitors; Humans; Mice; Mice, SCID; Multiple Myeloma; Nelfinavir; Pyrazines; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2013 |
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Genes, Reporter; Histone Deacetylase Inhibitors; HIV Protease Inhibitors; Humans; Luciferases; Mice; Multiple Myeloma; Nelfinavir; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2012 |